Abstract
The contribution of ABCG2 gene variants to hyperuricemia in Mexican patients with type 2 diabetes (T2D) remains uncertain, despite previously established associations in other populations. In this study, we analyzed the association of the ABCG2 gene variants rs2054576, rs2231142 and rs1001796 with serum uric acid (SUA) levels and hyperuricemia in patients with T2D and chronic kidney disease (CKD) from Mexico. This cross-sectional study involved the genotyping of 1,085 Mexican patients with T2D and 284 healthy subjects (HS) for the missense variant Q141K (rs2231142) and two intronic variants, rs2054576, and rs10011976 of the ABCG2 gene. Univariate and multivariate analyses were conducted to examine the association between ABCG2 genotypes and urate levels and hyperuricemia in relation to the presence of CKD. Clinical and biochemical parameters were also determined and compared. Serum uric acid concentrations and prevalence of hyperuricemia were higher in the patient group compared to healthy subjects. In the patient population, individuals with CKD demonstrated elevated SUA levels and a greater prevalence of hyperuricemia when compared to those without CKD (6.4 mg/dL vs. 5.0 mg/dL, p < 0.001 and 49% vs. 19%, p < 0.001), respectively). The rs2231142 variant showed a significant association with SUA concentrations among patients with T2D (β = 0.393; p = 0.017), as well as healthy individuals (β = 0.407; p = 0.005); however, no significant association was observed with hyperuricemia. In this cohort of Mexican patients with T2D, kidney disease was found as the primary factor associated with hyperuricemia. Additionally, rs2231142 was the only ABCG2 gene variant linked to SUA levels in both T2D patients and healthy individuals, though it was not associated with hyperuricemia. Nevertheless, genetic analysis of rs2231142 may contribute to the evaluation of T2D patients at risk for complications related to elevated uric acid.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
Estiverne, C., Mandal, A. K. & Mount, D. B. Molecular pathophysiology of uric acid homeostasis. Semin Nephrol. 40 (6), 535–549. https://doi.org/10.1016/j.semnephrol.2020.12.006 (2020).
Zhang, M. et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19. Front. Immunol. 12791983. https://doi.org/10.3389/fimmu.2021.791983 (2021).
Kim, Y., Kang, J. & Kim, G. T. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin. Rheumatol. 37 (9), 2529–2538. https://doi.org/10.1007/s10067-018-4130-2 (2018).
Chen-Xu, M., Yokose, C., Rai, S. K., Pillinger, M. H. & Choi, H. K. Contemporary prevalence of gout and hyperuricemia in the united States and decadal trends: the National health and nutrition examination Survey, 2007–2016. Arthritis Rheumatol. 71 (6), 991–999. https://doi.org/10.1002/art.40807 (2019).
Shamah-Levy, T. et al. Encuesta Nacional De Salud Y Nutrición Continua 2023. Resultados Nacionales (Instituto Nacional de Salud Pública, 2024).
Zhang, Z. et al. The new definition of metabolic syndrome including hyperuricemia improves its prognostic value: results from NHANES database. BMC Cardiovasc. Disord. 25 (1), 93. https://doi.org/10.1186/s12872-025-04529-7 (2025).
Nakayama, A. et al. Dysuricemia Biomedicines ;11(12). https://doi.org/10.3390/biomedicines11123169 (2023).
Lv, Q. et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 8 (2), e56864. https://doi.org/10.1371/journal.pone.0056864 (2013).
Kodama, S. et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 32 (9), 1737–1742. https://doi.org/10.2337/dc09-0288 (2009).
Liu, J. et al. Two-Year changes in hyperuricemia and risk of diabetes: A five-year prospective cohort study. J. Diabetes Res. 20186905720. https://doi.org/10.1155/2018/6905720 (2018).
Mortada, I. & Hyperuricemia Type 2 diabetes mellitus, and hypertension: an emerging association. Curr. Hypertens. Rep. 9 (69), 5. https://doi.org/10.1007/s11906-017-0770-x (2017).
Khosla, U. M. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67 (5), 1739–1742. https://doi.org/10.1111/j.1523-1755.2005.00273.x (2005).
Tu, J. et al. BMI mediates the association of serum uric acid with bone health: a cross-sectional study of the National health and nutrition examination survey (NHANES). BMC Musculoskelet. Disord. 25 (1), 482. https://doi.org/10.1186/s12891-024-07595-8 (2024).
Brandstatter, A. et al. Sex-specific association of the putative Fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care. 31 (8), 1662–1667. https://doi.org/10.2337/dc08-0349 (2008).
Chen, Y. J. et al. Association of ABCG2 rs2231142 allele and Bmi with hyperuricemia in an East Asian population. Front. Genet. 12709887. https://doi.org/10.3389/fgene.2021.709887 (2021).
Scheepers, L. et al. Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht study. J. Hypertens. 35 (10), 1968–1975. https://doi.org/10.1097/HJH.0000000000001417 (2017).
Mallat, S. G., Al Kattar, S., Tanios, B. Y. & Jurjus, A. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr. Hypertens. Rep. 18 (10), 74. https://doi.org/10.1007/s11906-016-0684-z (2016).
Leiba, A., Vinker, S., Dinour, D., Holtzman, E. J. & Shani, M. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J. Am. Soc. Hypertens. 9 (8), 600–609. https://doi.org/10.1016/j.jash.2015.05.010 (2015).
Li, Q. et al. Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease. Sci. Rep. 12 (1), 19988. https://doi.org/10.1038/s41598-022-23478-1 (2022).
Wang, L., Zhang, T., Liu, Y., Tang, F. & Xue, F. Association of serum uric acid with metabolic syndrome and its components: a Mendelian randomization analysis. Biomed. Res. Int. 20206238693. https://doi.org/10.1155/2020/6238693 (2020).
Jalal, D. I., Chonchol, M., Chen, W. & Targher, G. Uric acid as a target of therapy in CKD. Am. J. Kidney Dis. 61 (1), 134–146. https://doi.org/10.1053/j.ajkd.2012.07.021 (2013).
Miyazaki, R. et al. First verification of human small intestinal uric acid secretion and effect of ABCG2 polymorphisms. J. Transl Med. 23 (1), 257. https://doi.org/10.1186/s12967-025-06145-7 (2025).
Sarkadi, B., Homolya, L. & Hegedus, T. The ABCG2/BCRP transporter and its variants - from structure to pathology. FEBS Lett. https://doi.org/10.1002/1873-3468.13947 (2020).
Rivera-Paredez, B. et al. Influence of genetic and non-genetic risk factors for serum uric acid levels and hyperuricemia in Mexicans. Nutrients 11 (6). https://doi.org/10.3390/nu11061336 (2019).
Macias-Kauffer, L. R. et al. Genetic contributors to serum uric acid levels in Mexicans and their effect on premature coronary artery disease. Int. J. Cardiol. 279168–279173. https://doi.org/10.1016/j.ijcard.2018.09.107 (2019).
Yang, B. et al. A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. BMC Med. Genomics. 710. https://doi.org/10.1186/1755-8794-7-10 (2014).
Liu, J., Yang, W., Li, Y., Wei, Z. & Dan, X. ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population. BMC Med. Genet. 21 (1), 54. https://doi.org/10.1186/s12881-020-0987-4 (2020).
Liang, M. et al. Analysis of ABCG2 gene rs2231142 single nucleotide polymorphism and risk factors in hyperuricemia. Sci. Rep. 15 (1), 9679. https://doi.org/10.1038/s41598-025-93312-x (2025).
Hoque, K. M. et al. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat. Commun. 11 (1), 2767. https://doi.org/10.1038/s41467-020-16525-w (2020).
Pilon, M. O. et al. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites. Clin. Transl Sci. 15 (8), 2024–2034. https://doi.org/10.1111/cts.13318 (2022).
Lukkunaprasit, T. et al. The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis. BMC Med. Genet. 21 (1), 210. https://doi.org/10.1186/s12881-020-01147-2 (2020).
Dehghan, A. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372 (9654), 1953–1961. https://doi.org/10.1016/S0140-6736(08)61343-4 (2008).
Cleophas, M. C. et al. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmagenomics Pers. Med. 10129–10142. https://doi.org/10.2147/PGPM.S105854 (2017).
Son, C. N. et al. ABCG2 polymorphism is associated with hyperuricemia in a study of a community-based Korean cohort. J. Korean Med. Sci. 32 (9), 1451–1459. https://doi.org/10.3346/jkms.2017.32.9.1451 (2017).
Vazquez-Rivera, G. E. et al. Single nucleotide variants of the SLC2A9 gene are associated with hyperuricemia in Mexican patients with type 2 diabetes. Arch. Med. Res. 56 (6), 103235. https://doi.org/10.1016/j.arcmed.2025.103235 (2025).
Kim, G. H. & Jun, J. B. Altered serum uric acid levels in kidney disorders. Life (Basel). 12 (11). https://doi.org/10.3390/life12111891 (2022).
Wu, S., Kong, M., Song, Y. & Peng, A. Ethnic disparities in bidirectional causal effects between serum uric acid concentrations and kidney function: Trans-ethnic Mendelian randomization study. Heliyon 9 (11), e21108. https://doi.org/10.1016/j.heliyon.2023.e21108 (2023).
Lyngdoh, T. et al. Serum uric acid and adiposity: Deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 7 (6), e39321. https://doi.org/10.1371/journal.pone.0039321 (2012).
Liu, J. et al. Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women. Int. Urol. Nephrol. 49 (11), 2035–2042. https://doi.org/10.1007/s11255-017-1686-8 (2017).
Hsieh, Y. P. et al. The role of uric acid in chronic kidney disease patients. Nephrol. (Carlton). 22 (6), 441–448. https://doi.org/10.1111/nep.12679 (2017).
American Diabetes, A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 43(Suppl 1), S14-S31. (2020). https://doi.org/10.2337/dc20-S002
KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19–62. (2011). https://doi.org/10.1038/kisup.2012.64
Levey, A. S. & Stevens, L. A. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am. J. Kidney Dis. 55 (4), 622–627. https://doi.org/10.1053/j.ajkd.2010.02.337 (2010).
Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular Cloning: a Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989).
Mannino, G. C. et al. The polymorphism rs35767 at IGF1 locus is associated with serum urate levels. Sci. Rep. 8 (1), 12255. https://doi.org/10.1038/s41598-018-29665-3 (2018).
Bardin, T. & Richette, P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 15 (1), 123. https://doi.org/10.1186/s12916-017-0890-9 (2017).
De Cosmo, S. et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin. J. Am. Soc. Nephrol. 10 (11), 1921–1929. https://doi.org/10.2215/CJN.03140315 (2015).
Zhou, Y., Wang, H. & Gao, W. Elevated blood glucose can promote uric acid excretion: a cross-sectional study involving urinary glucose and urinary uric acid in China. Diabetes Metab. Syndr. Obes. 174553–174563. https://doi.org/10.2147/DMSO.S472686 (2024).
Sesti, G. et al. Low Circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr. Metab. Cardiovasc. Dis. 24 (12), 1365–1372. https://doi.org/10.1016/j.numecd.2014.06.012 (2014).
Novikov, A. et al. SGLT2 Inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am. J. Physiol. Ren. Physiol. 316 (1), F173–F185. https://doi.org/10.1152/ajprenal.00462.2018 (2019).
Cheserek, M. J., Shi, Y. & Le, G. Association of hyperuricemia with metabolic syndrome among university workers: sex and occupational differences. Afr. Health Sci. 18 (4), 842–851. https://doi.org/10.4314/ahs.v18i4.2 (2018).
Kumagai, T. et al. Time to target uric acid to retard CKD progression. Clin. Exp. Nephrol. 21 (2), 182–192. https://doi.org/10.1007/s10157-016-1288-2 (2017).
Hisatome, I. et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease - Japanese guideline on the management of asymptomatic hyperuricemia. Circ. J. 85 (2), 130–138. https://doi.org/10.1253/circj.CJ-20-0406 (2021).
Nakayama, S. et al. Detailed association between serum uric acid levels and the incidence of chronic kidney disease stratified by sex in middle-aged adults. Atherosclerosis 330107–330113. https://doi.org/10.1016/j.atherosclerosis.2021.06.908 (2021).
Son, Y. B. et al. The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: A health checkup cohort study. PLoS One. 16 (1), e0244106. https://doi.org/10.1371/journal.pone.0244106 (2021).
Chang, Y. H. et al. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab. Res. Rev. 32 (6), 557–564. https://doi.org/10.1002/dmrr.2768 (2016).
Ohta, Y. et al. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertens. Res. 40 (3), 259–263. https://doi.org/10.1038/hr.2016.139 (2017).
Brandstatter, A. et al. Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis 210 (2), 474–478. https://doi.org/10.1016/j.atherosclerosis.2009.12.013 (2010).
Xiang, R. et al. Recent advances in polygenic scores: translation, equitability, methods and FAIR tools. Genome Med. 16 (1), 33. https://doi.org/10.1186/s13073-024-01304-9 (2024).
Acknowledgements
We thank Jazmin Martín del Campo for her valuable assistance in patient recruitment and laboratory sample processing.
Funding
This research was funded by Fundación IMSS (Number: R-2021-1305-007), granted to F.M.C. G.E.V.R. received a postgraduate fellowship (fellow number: 967146) from the Consejo Nacional de Humanidades, Ciencia y Tecnología (CONAHCyT).
Author information
Authors and Affiliations
Contributions
F.M.C: Conceptualization, funding adquisition, project administration, draft-writing, discussion and reviewing the manuscript. G.E.V.R: Sample analysis, data collection, discussion and reviewing the manuscript. E.F.G.G: Sample analysis, data collection, discussion and reviewing the manuscript. R.P.M: Patient recruitment, discussion and reviewing the manuscript. R.O.S: Patient recruitment, discussion and reviewing the manuscript. L.C.R.T: Sample processing and analysis, discussion and reviewing the manuscript. A.C.G.R: Sample analysis, data collection, discussion and reviewing the manuscript. A.F.B: Sample analysis, data collection, discussion and reviewing the manuscript. C.A.L.C: Sample analysis, discussion and reviewing the manuscript. All authors have read and agreed to this version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Mendoza-Carrera, F., Vázquez-Rivera, G.E., Gómez-García, E.F. et al. Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease. Sci Rep (2026). https://doi.org/10.1038/s41598-026-35853-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-35853-3